Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors that Express HER2

    Cancer Categories
    • Gastrointestinal (GI),Gynecologic,Head and Neck,Lung,Skin
    Karmanos Trial ID
    • 2023-069
    NCT ID
    • NCT06003231
    Age Group
    • Adult
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase II
    Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
    • Phase II
    Principal Investigator


    Primary Objective:

    • To evaluate the antitumor activity of disitamab vedotin in subjects with previously treated, locally-advanced unresectable or metastatic (LA/m) HER2 expressing solid tumors

    Secondary Objectives:

    • To evaluate the safety and tolerability profile of disitamab vedotin
    • To assess other measures of antitumor activity of disitamab vedotin per investigator assessment by other clinically relevant measures
    • To evaluate the pharmacokinetics (PK) of disitamab vedotin
    • To evaluate the immunogenicity of disitamab vedotin
  • Locations


    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266